<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02251223</url>
  </required_header>
  <id_info>
    <org_study_id>1182.6</org_study_id>
    <nct_id>NCT02251223</nct_id>
  </id_info>
  <brief_title>Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects</brief_title>
  <official_title>An Open Label Multinational Study of the Effects of Three Dose Pairs of Tipranavir/Ritonavir (b.i.d.) on the Pharmacokinetic Characteristics of Protocol -Defined, Baseline, Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Primary: Sequentially determine the effects of three dose combinations of tipranavir (TPV) /&#xD;
      ritonavir (RTV) (administered b.i.d.), TPV 1250 mg/RTV 100 mg vs. TPV 750 mg/RTV 100 mg vs.&#xD;
      TPV 250 mg/RTV 200 mg on the steady-state pharmacokinetics of zidovudine, lamivudine,&#xD;
      stavudine, didanosine, abacavir, nevirapine and efavirenz at approved doses. The three&#xD;
      treatment groups will be enrolled sequentially starting with the highest tipranavir dosage&#xD;
      group first and ending with the lowest tipranavir dosage group.&#xD;
&#xD;
      Secondary: A) To assess the effects of zidovudine, lamivudine, stavudine, didanosine,&#xD;
      abacavir, nevirapine, and efavirenz on the pharmacokinetics of tipranavir/ritonavir compared&#xD;
      to historical controls.&#xD;
&#xD;
      B) To assess the safety of three tipranavir/ritonavir combinations when used in combination&#xD;
      with protocol defined antiretrovirals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <primary_completion_date type="Actual">February 2002</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Change in trough plasma concentration (Cmin,ss) for non-nucleoside reverse transcriptase inhibitor (NNRTI)</measure>
    <time_frame>baseline, up to day 23</time_frame>
    <description>stratified by substance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in area under plasma concentration-time curve over dosing interval (AUC0-τ) for nucleoside reverse transcriptase inhibitor (NRTI)</measure>
    <time_frame>baseline, up to day 22</time_frame>
    <description>stratified by substance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in area under plasma concentration-time curve from 0 to 12 hours for didanosine (ddI)</measure>
    <time_frame>baseline, up to day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss</measure>
    <time_frame>up to day 23</time_frame>
    <description>stratified by substance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-τ</measure>
    <time_frame>up to day 23</time_frame>
    <description>stratified by substance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>up to day 23</time_frame>
    <description>stratified by substance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum plasma concentration (Tmax)</measure>
    <time_frame>up to day 23</time_frame>
    <description>stratified by substance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance (Cl/F)</measure>
    <time_frame>up to day 23</time_frame>
    <description>stratified by substance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half life (t1/2)</measure>
    <time_frame>up to day 23</time_frame>
    <description>stratified by substance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 cell count</measure>
    <time_frame>up to day 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1 RNA levels</measure>
    <time_frame>up to day 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant findings in laboratory tests</measure>
    <time_frame>up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 25 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>TPV/r low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TPV/r medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TPV/r high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir low dose</intervention_name>
    <arm_group_label>TPV/r low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir medium dose</intervention_name>
    <arm_group_label>TPV/r medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir high dose</intervention_name>
    <arm_group_label>TPV/r high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir low dose</intervention_name>
    <arm_group_label>TPV/r high dose</arm_group_label>
    <arm_group_label>TPV/r medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir high dose</intervention_name>
    <arm_group_label>TPV/r low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent prior to trial participation&#xD;
&#xD;
          2. Between 18 and 75 years of age inclusive&#xD;
&#xD;
          3. Female subjects of child bearing potential are required to use a barrier contraceptive&#xD;
             method for at least 12 weeks prior to administration of study medication, during study&#xD;
             medication administration, and for 28 days after the end of the study&#xD;
&#xD;
          4. Ability to swallow capsules without difficulty&#xD;
&#xD;
          5. A Body Mass Index (BMI) between 11 and 50 kg/m2&#xD;
&#xD;
          6. Reasonable probability for completion of the study&#xD;
&#xD;
          7. Acceptable screening laboratory values. All laboratory values ≤ Grade I (e.g.,&#xD;
             creatine phosphokinase (CPK), amylase, triglycerides) are permissible if documentation&#xD;
             of stability for 2 months or more is available. Abnormalities &gt; Grade I are subject to&#xD;
             approval by BI clinical monitor or designee&#xD;
&#xD;
          8. Acceptable medical history, physical examination, ECG, and chest X-ray prior to&#xD;
             entering the treatment phase of the study&#xD;
&#xD;
          9. Willingness to abstain from alcohol from Day -2 to Day 23&#xD;
&#xD;
         10. Willingness to abstain from ingesting grapefruit, grapefruit juice, Seville oranges or&#xD;
             orange marmalade from Day -2 to Day 23&#xD;
&#xD;
         11. Negative urine drug screen for drugs of abuse. Subjects on methadone or equivalent&#xD;
             narcotic maintenance programs will be permitted to enter the study&#xD;
&#xD;
         12. Documented HIV-1 RNA load (by PCR) at screening of ≤20,000 copies/mL for at least&#xD;
             twelve weeks. Acceptable documentation would include laboratory data, a letter or a&#xD;
             verbal report from another provider noted in the subject records.&#xD;
&#xD;
         13. Stable doses of approved NRTIs and NNRTIs 2 for a minimum of twelve weeks prior to&#xD;
             study Day 0. Subjects on efavirenz must be able to tolerate daily morning (8:00 a.m.)&#xD;
             dosing starting at screening period and for 22 days of the study. Subjects receiving&#xD;
             bid ddI must be willing to accept a change to the once a day delayed release (EC)&#xD;
             formulation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects who:&#xD;
&#xD;
               -  have a positive serum pregnancy test at Screening Period Day -14 to -7&#xD;
&#xD;
               -  are breast feeding&#xD;
&#xD;
          2. Receipt of any other investigational medicine for 30 days prior to Day 0&#xD;
&#xD;
          3. Receipt of any known cytochrome P450 3A4 (CYP3A4) altering drug i.e. phenothiazines,&#xD;
             cimetidine, barbiturates, ketoconazole, fluconazole, rifampin, steroids and herbal&#xD;
             medications for 30 days prior to Day 0. No antibiotics permitted within 10 days prior&#xD;
             to Day 0&#xD;
&#xD;
          4. Ingestion of grapefruit, grapefruit juice, Seville oranges or orange marmalade within&#xD;
             2 days of study entry (Day 0)&#xD;
&#xD;
          5. Blood or plasma donations (&gt;100 ml total) for research or altruistic reasons within 30&#xD;
             days prior to Day 0&#xD;
&#xD;
          6. Seated systolic blood pressure either &lt;100 mm Hg or &gt;150 mm Hg; resting heart rate&#xD;
             either &lt;50 beats/minute or &gt;90 beats/minute&#xD;
&#xD;
          7. History of any illness, including malabsorption, irregular food intake or&#xD;
             gastrointestinal intolerance, or allergy that, in the opinion of the investigator,&#xD;
             might confound the results of the study or pose additional risk in administering&#xD;
             TPV/RTV&#xD;
&#xD;
          8. Any acute illness within 2 weeks prior to Day 0&#xD;
&#xD;
          9. Subjects who are currently taking any over-the-counter drug within 7 days prior to Day&#xD;
             0, or who are currently taking any prescription drug that, in the opinion of the&#xD;
             investigator (in consultation with the BI medical monitor and/or pharmacokineticist),&#xD;
             might interfere with either the absorption, distribution or metabolism of the TPV/RTV&#xD;
&#xD;
         10. Hypersensitivity to TPV, RTV or sulfonamide containing drugs&#xD;
&#xD;
         11. Using the adherence diary, subject has less than 100% documented adherence for the&#xD;
             last 14 doses (7 days) of baseline antiretroviral medications prior to Day 0. Subjects&#xD;
             has less than 100% adherence for the last 7 doses (7 days) of efavirenz and ddI&#xD;
             (delayed release) prior to Day 0&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>September 25, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2014</study_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

